Leerink analyst David Risinger raised the firm’s price target on Vaxcyte to $153 from $106 and keeps an Outperform rating on the shares following “stunning” VAX-31 Phase 1/2 adult results that exceeded expectations and the firm describes as a “home run.” The firm, which believes that the VAX-31 adult data represents a “significant derisking,” increased its estimated total probability-adjusted 2032 VAX-24/31 worldwide sales for adults and infants to $5.0B from $2.3B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Needham ups Vaxcyte target to $140 after ‘best-case scenario’ data
- Vaxcyte price target raised to $140 from $95 at Needham
- ESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
- Vaxcyte price target raised to $160 from $98 at BTIG
- Morning Movers: U.S. Steel drops after VP Harris opposes sale to Nippon